Hematology Oncology Market, By Hematology Product (Hematology Analyzers, Hematology Reagents, Flow Cytometers, Hematology Cell Counters, Slide Strainers, Coagulation Analyzers, Hematology Testing, Centrifuges, Hemoglobin meters, Others), By Oncology Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy), By Oncology Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, Others), By Applications, By End Users and By Region- Market Trends, Analysis, and Forecast till 2030

Hematology Oncology Market accounted for USD 2.21 billion in 2020 and is estimated to be USD 6.57 billion by 2030 and is anticipated to register a CAGR of 11.5%.

Hematology is the study of blood and bone marrow illnesses, as well as their diagnosis, prevention, and therapy. Oncology is the branch of medicine that deals with the prevention, treatment, and diagnosis of cancer. Hematology is used in a variety of settings, including cardiovascular disease, diabetes, cancer, and blood screening. Medical, surgical, and radiation oncology are the three main areas where oncology is used. Hemato oncology testing examines blood abnormalities in the medical sector, such as iron deficiency anaemia, haemophilia, sickle cell disease, leukemias, lymphomas, and malignancies of various organs. Hematologists and oncologists commonly collaborate to treat serious diseases such as leukaemia and lymphoma, and haematologists and oncologists often work together to treat these diseases. The entire hemato oncology testing will be reliable and successful as a result of technological advancements and accurate information use. Hematological oncology play an important role in the detection and treatment of cancers of the bone marrow, blood, and lymph nodes. The COVID-19 pandemic has disrupted the most critical parts of the oncology pharmaceuticals business by disrupting clinical studies and drug delivery to patients. The pandemic has had a direct impact on cancer patients' access to oncology drugs; not only is it difficult to administer chemotherapy and other treatments outside of a clinic, but the spread of coronavirus has reduced patients' willingness and ability to access not only treatments, but also clinical trials for new medicines.

Rising prevalence of lymphoma and myeloma will drive the growth of the Market

One of the primary factors driving the growth of the haematology oncology market is the rising prevalence of lymphoma and myeloma around the world. The rise in the availability of improved molecular techniques for the diagnosis of hemato oncology, as well as the proliferation of sequencing techniques such as NGS due to the rise in cost of development and sequencing of the Human Genome Project in the field of genomics, are driving market expansion. The advent of sophisticated molecular techniques in addressing issues about blood cancer prognosis, treatment course, and diagnosis, as well as an increase in the number of instances of blood disorders, are all factors that have an impact on the market. Furthermore, attractive reimbursement procedures, pharmaceutical company partnership, and an increase in healthcare expenditure all benefit the haematological oncology industry. Furthermore, in the projected period of 2021 to 2028, a surge in the co-development of the drug-diagnostics model would provide profitable opportunities to market players.

Increased cancer prevalence and incidence of various cancer disorders, as well as increased popularity of advanced therapies (biological and targeted medication therapies) and an increase in the global elderly population. Furthermore, increased cancer awareness and early cancer screening contribute to the growth of the oncology medications industry. However, the high costs associated with new medication development, as well as the risk of failure and side effects associated with cancer treatment therapies, are limiting the market's expansion. Conversely, during the projected period, the high potential of rising economies and the greater number of prospective medications in the pipeline are expected to provide profitable prospects.

The Global Hematology Oncology Market is segmented based on Hematology Product, Oncology Drug Class, Oncology Indication, Application, End-User and region.

On the basis of Hematology Product, the Global Hematology Oncology Market is segmented into Hematology Analyzers, Hematology Reagents, Flow Cytometers, Hematology Cell Counters, Slide Strainers, Coagulation Analyzers, Hematology Testing, Centrifuges, Hemoglobin meters, Others. Based on Oncology Drug Class, the target market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy. Based on Oncology Indication, the target market is segmented into Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, Others. Based on Application, the target market is segmented into Infectious Diseases, Cancer, Cardiovascular Disorders, Blood Screening, Diabetes, HIV, Auto – Immune Diseases. Based on End-User, the target market is segmented into Hospitals, Clinical Testing Institutes, Patient Self- Testing, Other End- Users.

Regional Insights:                                                                                  

On region the Global Hematology Oncology Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Due to the rising frequency of leukaemia, lymphoma, and multiple myeloma in the region, North America dominates the haematology oncology industry. Due to the expanding number of research activities done by various academic research institutes in the region, Asia-Pacific is predicted to have considerable increase over the forecast period of 2021 to 2030.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the Global Hematology Oncology Market report based on Hematology Product, Oncology Drug Class, Oncology Indication, Application, End-User and region.

Global Hematology Oncology Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating in the hematology oncology market are Abbott Laboratories, Bio-Rad Laboratories, Inc., Danaher, Thermo Fisher Scientific Inc., AbbVie Inc., Astellas Pharma Inc., AstraZeneca, Bristol-Myers Squibb Company, CELGENE CORPORATION, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Boule, Sysmex Corporation, Beckman Coulter, Inc., F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, and PerkinElmer Inc., among other domestic and global players.

• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Danaher
• Thermo Fisher Scientific Inc.
• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca
• Bristol-Myers Squibb Company